1. Home
  2. DCBO vs CRVS Comparison

DCBO vs CRVS Comparison

Compare DCBO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$18.56

Market Cap

632.5M

Sector

N/A

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$20.50

Market Cap

546.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
CRVS
Founded
2016
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
632.5M
546.7M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
DCBO
CRVS
Price
$18.56
$20.50
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$34.67
$28.00
AVG Volume (30 Days)
87.0K
7.5M
Earning Date
02-27-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
32.42
N/A
EPS
0.74
N/A
Revenue
$236,691,000.00
N/A
Revenue This Year
$13.67
N/A
Revenue Next Year
$7.43
N/A
P/E Ratio
$25.45
N/A
Revenue Growth
13.16
N/A
52 Week Low
$18.11
$2.54
52 Week High
$43.84
$26.95

Technical Indicators

Market Signals
Indicator
DCBO
CRVS
Relative Strength Index (RSI) 26.21 70.64
Support Level $18.11 $20.70
Resistance Level $19.08 $26.95
Average True Range (ATR) 0.71 2.08
MACD -0.19 1.37
Stochastic Oscillator 8.86 69.50

Price Performance

Historical Comparison
DCBO
CRVS

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: